35 results about "Platelet aggregation ratio" patented technology

The invention discloses a medicament for treating the chronic cerebral circulation insufficiency and a preparation method. The medicament comprises salvia, codonopsis, coptis, chuanxiong, zedoary, crataegus, seaweed, gastrodia, coix seed and curcuma as raw materials. The preparation method comprises the following steps of: adding water to the coptis for decoction, concentrating the water decoction into thick paste, adding water to other raw materials for decoction, concentrating the water decoction into thick paste, combing the two pieces of thick paste, adding a suitable amount of dextrin, and uniformly mixing, drying, crushing and pelletizing the mixture. The medicament has the effects of simultaneously removing blood stasis, promoting blood circulation, eliminating phlegm and invigorating spleen, can better treat the arteriosclerosis, remarkably improve the integral of syndrome of intermingled phlegm and blood stasis for the granule fraction of removing blood stasis and promoting blood circulation, has better effects of reducing the whole blood high-shear viscosity, low-shear viscosity, plasma viscosity and platelet aggregation ratio, and has the advantages of high safety and no influence on hemogram, liver and kidney functions and the like.

The invention provides a method for judging the measurement result of platelet aggregation rate, comprising the following steps: selecting a normal whole blood sample, measuring the transmittance PPP0 of platelet-poor plasma and the transmittance PRP0 of platelet-rich plasma, and calculating the ratio of the transmittance of the whole blood sample Difference P0=PPP0-PRP0; select the whole blood sample to be tested, measure the platelet-poor plasma transmittance PPP and platelet-rich plasma transmittance PRP, and calculate the difference between the transmittance of the tested sample P=PPP-PRP; calculate the measured The platelet separation index DI=P / P0=(PPP-PRP) / (PPP0-PRP0) of the sample; the platelet aggregation rate of platelet-rich plasma is measured by a platelet aggregometer; according to the platelet separation index DI of the tested sample, the determination measurement Whether the platelet aggregation rate is reliable. The invention reliably judges the measurement result of the platelet aggregation rate of the tested sample by referring to the platelet separation index of the tested sample.

A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.

The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-III derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-III derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.

In this invention, we extract raw polysaccharides from changium root named A B C respectively, and purify to get 6 polysaccharides I,II,III,IV,V,VI. After sulfation, we get sulfated polysaccharides A1, B1,C1. A1 has two sulfate groups on each monosaccharide at the average while B1 and C1 have three. The sulfated polysaccharides' molecular weight is more than 2 million D. The glycoside link is alpha type. The whole procedure of changium root sulfated polysaccharides is as followings: extract raw polysaccharides from changium root, and then get the polysaccharides sulfated. It is advantageous in simplied-manipulation and low cost. The pharmacological experiments prove its obvious suppression on rat transplanting tumor(S-180) and the reduction of platelet aggregation ratio and whole blood viscosity. It also reduces coagulant time.